Document and Entity Information - USD ($) $ in Millions |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2025 |
Mar. 17, 2026 |
Jun. 30, 2024 |
|
| Cover [Abstract] | |||
| Registrant Name | MEDICUS PHARMA LTD. | ||
| Registrant CIK | 0001997296 | ||
| Current Fiscal Year End Date | --12-31 | ||
| Document Type | 10-K | ||
| Document Annual Report | true | ||
| Entity File Number | 001-42408 | ||
| Document Financial Statement Error Correction [Flag] | false | ||
| Document Period End Date | Dec. 31, 2025 | ||
| Document Fiscal Year Focus | 2025 | ||
| Document Fiscal Period Focus | FY | ||
| Entity Incorporation, State or Country Code | A6 | ||
| Entity Tax Identification Number | 98-1778211 | ||
| Entity Address, Address Line One | 300 Conshohocken State Rd. | ||
| Entity Address, City or Town | W. Conshohocken | ||
| Entity Address, State or Province | PA | ||
| Entity Address, Postal Zip Code | 19428 | ||
| City Area Code | 610 | ||
| Local Phone Number | 636-0184 | ||
| Title of 12(g) Security | Common shares, no par value | ||
| Trading Symbol | MDCX | ||
| Security Exchange Name | NASDAQ | ||
| Entity Well-known Seasoned Issuer | No | ||
| Entity Voluntary Filers | No | ||
| Entity Current Reporting Status | Yes | ||
| Entity Interactive Data Current | Yes | ||
| Entity Filer Category | Non-accelerated Filer | ||
| Entity Small Business | true | ||
| Entity Emerging Growth Company | true | ||
| Entity Shell Company | false | ||
| Entity Public Float | $ 28.3 | ||
| Entity Common Stock, Shares Outstanding | 39,362,109 | ||
| Amendment Flag | false | ||
| Document Transition Report | false | ||
| Entity Ex Transition Period | false | ||
| Auditor Firm ID | 185 | ||
| Auditor Name | KPMG LLP | ||
| Auditor Location | New York, New York | ||
| Documents Incorporated by Reference |
The information required by Part III of this Annual Report, to the extent not set forth herein, is incorporated herein by reference from the registrant's definitive proxy statement relating to the Annual Meeting of Shareholders to be held in 2025, which definitive proxy statement shall be filed with the Securities and Exchange Commission within 120 days after the end of the fiscal year to which this Annual Report relates, unless such definitive proxy statement is not filed prior to 120 days after the end of the fiscal year to which this Annual Report relates, in which case the information relating to this item will be filed by amendment to this Annual Report. |
||
| Auditor Opinion |
Opinion on the Consolidated Financial Statements We have audited the accompanying consolidated balance sheet of Medicus Pharma Ltd. and subsidiaries (the Company) as of December 31, 2025, the related consolidated statements of operations and comprehensive loss, changes in shareholders' equity, and cash flows for the year then ended, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025, and the results of its operations and its cash flows for the year then ended, in conformity with U.S. generally accepted accounting principles. |
||
| Rule 10b5-1 Arrangement Terminated [Flag] | true |